Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA engages in the research and development of drugs for the treatment of central nervous system disorders and pain.

It operates through a single segment which is the Research and Development of Pharmaceutical drugs.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20122013Delta
CHF (in Million)%CHF (in Million)%
Pharmaceuticals10.73100%3.95100% -171.43%
Managers
NameAgeSinceTitle
Stefan Weber492005Chief Executive Officer, MD, Director & IR Contact
Ulrich Köstlin, PhD622013Non-Executive Chairman
Roberto Galli-2002VP-Finance & Investor Relations Contact
Ravi Anand, MD572005Chief Medical Officer
Patrick J. Langlois, PhD682008Independent Director
Hanns Moehler, MD-2008Non-Executive Director
Roberto Consonni-2012Non-Executive Director
Robert Leslie Holland MD, PhD592013Non-Executive Director
Bo Jesper Hansen MD, PhD552013Non-Executive Director
Marco Caremi572002Executive Vice President-Business Development
Shareholders
NameShares%
Investor AB 1,665,73312.8%
Gefim SpA 1,484,19511.4%
JPMorgan Asset Management (UK) Ltd. 611,4734.70%
Swisscanto Asset Management AG 201,9871.55%
Polar Capital LLP 105,5090.81%
Aviva Investors Global Services Ltd. 103,6920.80%
Michel & Cortesi Asset Management AG 64,2140.49%
AXA Investment Managers (Paris) SA 60,0000.46%
Credit Suisse AG 54,1610.42%
Pictet Asset Management SA 29,5300.23%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER -
Potential -
Yield -
Consensus -
7 days EPS revision -
4 months EPS revision
1 year EPS revision -
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ITI INC
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
INTERCEPT PHARMAC..
MANNKIND CORPORAT..
BEIJING SL PHARMA..
NPS PHARMACEUTICA..
HUALAN BIOLOGICAL..
GENMAB A/S
TONGHUA DONGBAO P..
GW PHARMACEUTICAL..
BIOCON LTD
MEDIGEN BIOTECHNO..
-
KERYX BIOPHARMACE..
AGIOS PHARMACEUTI..
OPHTHOTECH CORP
DYAX CORP.
CLOVIS ONCOLOGY I..
ACORDA THERAPEUTI..
Sector Biotechnology & Medical Research
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF